-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoGenome-Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation Target
This pathway, which the authors dub the “BACH2-NRF2 axis,” is independent of the well-known BCL11A transcription regulator, the target of the approved cell therapy Casgevy for...
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoFour-year data raise durability questions for uniQure’s Huntington gene therapy
BIOCENTURY | PRODUCT DEVELOPMENTFOUR-YEAR DATA RAISE DURABILITY QUESTIONS FOR UNIQURE’S HUNTINGTON GENE THERAPYSmaller effect on composite endpoint clouds outlook, while functional capacity results preserve case for...
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoUniQure tumbles with latest data for Huntington’s gene therapy
Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoCurrent Challenges in CAR T Manufacturing
Predictive cell intelligence can be used to reveal cellular states and emerging cellular trajectories earlier in the manufacturing process and to support more informed bioprocessing decisions....
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agouniQure falls on long-term Huntington’s gene therapy data
uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoUniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for...
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoSTAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
UniQure's gene therapy continues to slow Huntington's progression after four years. But the magnitude of the benefit waned compared to a similar analysis from a year...
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agouniQure stock crashes as Huntington’s gene therapy data weaken
uniQure’s Huntington’s disease gene therapy has failed to significantly slow disease progression after 48 months, sending the biotech’s stock down 41% when trading began. But mitigating...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoCAR T start-up Link Cell names BMS, SystImmune vet Jie D’Elia CEO
BIOCENTURY | MANAGEMENT TRACKSCAR T START-UP LINK CELL NAMES BMS, SYSTIMMUNE VET JIE D’ELIA CEOIovance alum Friedrich Graf Finckenstein is CMO, co-founder Brian Slingerland becomes Executive Chair
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoWhen microbial DNA is scarce, new profiling method helps separate genuine signals from contamination
In acute, life-threatening infections, rapidly characterizing the microorganisms in a patient sample can help guide diagnosis and treatment. Computational methods known as taxonomic profilers can analyze...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
